Shefali Agarwal - 02 Feb 2022 Form 4 Insider Report for Epizyme, Inc. (EPZM)

Role: Executive Vice President, Chief Medical and Development Officer
Signature: /s/ John Weidenbruch, attorney-in-fact
Issuer symbol: EPZM
Transactions as of: 02 Feb 2022
Transactions value $: -$3,615
Form type: 4
Filing time: 04 Feb 2022, 15:15:25 UTC
Previous filing: 28 Jan 2022
Next filing: 09 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EPZM	Common Stock, par value $0.0001	Sale	-$3,615	-2,639	-1.6%	$1.37	157,443	02 Feb 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of Common Stock automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted under the Company's 2013 Stock Incentive Plan on February 1, 2021. The automatic sale of the reporting person's shares of Common Stock is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person.

Content

Represents shares of Common Stock automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted under the Company's 2013 Stock Incentive Plan on February 1, 2021. The automatic sale of the reporting person's shares of Common Stock is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person.

Remarks:

Executive Vice President, Chief Medical and Development Officer